keyword
MENU ▼
Read by QxMD icon Read
search

Central retinal vein

keyword
https://www.readbyqxmd.com/read/28432581/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-macular-oedema-due-to-branch-retinal-vein-occlusion-a-pilot-study
#1
M A Khan, Varakutti Mallika, Dattakiran Joshi
PURPOSE: To compare visual and anatomical recovery of immediate versus deferred intravitreal Bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO). METHODS: In a pilot study, 40 treatment naïve patients of branch retinal vein occlusion with macular oedema and vision 6/12 or less presenting within one month of onset were randomised into 2 groups (20 each) to receive either immediate intravitreal Bevacizumab or deferred (after 3 months of observation)...
April 21, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28427057/long-term-anatomical-and-functional-outcomes-in-patients-with-ischemic-central-retinal-vein-occlusion-treated-with-anti-vascular-endothelial-growth-factor-agents
#2
Irini Chatziralli, George Theodossiadis, Efstratios Parikakis, Panagiotis G Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To evaluate the anatomical and functional outcomes in patients with ischemic central retinal vein occlusion (CRVO) treated with intravitreal anti-vascular endothelial growth factor (VEGF) agents. METHODS: This retrospective study included 15 treatment-naive patients with ischemic CRVO and macular edema who were treated with intravitreal ranibizumab or aflibercept. The main outcomes were the evolution of retinal ischemia over time, as well as the change in best corrected visual acuity (BCVA) and in central subfield thickness (CST) at month 24...
April 21, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28405787/outcomes-of-switching-treatment-to-aflibercept-in-patients-with-macular-oedema-secondary-to-central-retinal-vein-occlusion-refractory-to-ranibizumab
#3
Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T Tsaousis, Konstantina Gorgoli, Somnath Banerjee, Theodoros Empeslidis
PURPOSE: To assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO). METHODS: A prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection...
April 12, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28399772/nurse-led-ranibizumab-intravitreal-injections-in-wet-age-related-macular-degeneration-a-literature-review
#4
Emma Gregg
Aim The aim of this literature review was to explore the development of the role of specialist ophthalmic nurses in delivering ranibizumab intravitreal injections to patients with wet age-related macular degeneration (AMD), and to evaluate their contribution to reducing capacity pressures in medical retina services, while maintaining safe and effective standards of care. Method A systematic literature search was undertaken to identify relevant articles published between January 2000 and June 2015. A search of electronic databases was undertaken, and selected relevant journals were searched manually...
April 12, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28384724/gap-in-capillary-perfusion-on-optical-coherence-tomography-angiography-associated-with-persistent-macular-edema-in-branch-retinal-vein-occlusion
#5
Kotaro Tsuboi, Yuichiro Ishida, Motohiro Kamei
Purpose: To evaluate correlations between persistent macular edema associated with branch retinal vein occlusion (BRVO) and the macular perfusion status in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) using optical coherence tomography angiography (OCTA). Methods: Retrospective, case-control study. Twenty patients with BRVO followed for 12 months or more were enrolled. Persistent macular edema was defined as central retinal thickness exceeding 300 μm that persisted or recurred less than 3 months after the final treatment...
April 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28379652/quantitative-reduction-in-central-foveal-thickness-after-first-anti-vegf-injection-as-a-predictor-of-final-outcome-in-brvo-patients
#6
Rupak Roy, Kumar Saurabh, Avirupa Ghose, Dhileesh P Chandrasekharan, Preeti Sharma, Swakshyar Saumya Pal, Sudipta Das
PURPOSE: To analyze the predictive ability of quantitative reduction in central foveal thickness (CFT) after the first antivascular endothelial growth factor (anti-VEGF) injection to assess final outcome in branch retinal vein occlusion (BRVO) patients. DESIGN: A retrospective interventional consecutive case series. METHODS: We retrospectively reviewed 60 treatment-naive BRVO patients. All the patients were treated with bevacizumab injection pro re nata...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#7
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28367038/dexamethasone-intravitreal-implant-rescue-treatment-for-bevacizumab-refractory-macular-edema-secondary-to-branch-retinal-vein-occlusion
#8
Kyou Ho Lee, Eui Chun Kang, Hyoung Jun Koh
PURPOSE: To evaluate the prognostic factors and outcomes of dexamethasone intravitreal implant (DEX implant) for intravitreal bevacizumab refractory macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional case series. Medical records were reviewed, and a total of 38 eyes that were treated with DEX implant for macular edema secondary to BRVO that did not respond to at least two consecutive intravitreal bevacizumab injections (IBIs) were included...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28367036/natural-short-term-course-of-recurrent-macular-edema-following-intravitreal-bevacizumab-therapy-in-branch-retinal-vein-occlusion
#9
Su Jin Yoo, Jae Hui Kim, Tae Gon Lee, Jong Woo Kim, Sung Won Cho, Jung Il Han
PURPOSE: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab. METHODS: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edema was either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treated group)...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28365905/aflibercept-a-review-in-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#10
Sheridan M Hoy
Aflibercept (Eylea(®)) is a fully human, recombinant fusion protein available in various countries worldwide, including those of the EU, as well as the USA, for intravitreal use in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) in adults. Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor (VEGF)-A and placental growth factor (PIGF), preventing these angiogenic factors from binding to and activating their cognate receptors...
April 1, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28358953/a-new-method-of-magnification-correction-for-accurately-measuring-retinal-vessel-calibers-from-fundus-photographs
#11
Aiko Iwase, Akihiko Sekine, Jun Suehiro, Kenji Tanaka, Yumiko Kawasaki, Ryo Kawasaki, Michael J Sinai, Makoto Araie
Purpose: To report a semiautomated retinal vessel caliber measurement system that measures central retinal artery (vein) equivalent (CRAE [CRVE]) with individual correction for magnification errors under conditions assuming optimal focus. Methods: The focusing condition of the subject eye fundus camera optical system was individually determined by constructing an optical model of each eye applying its refractive error, corneal curvature, and axial length (AL) to Gullstrand's schematic eye, and by adjusting the position of the camera's focusing lenses using each eye's refractive error...
March 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28345544/retinal-vascular-morphological-changes-in-patients-with-extremely-severe-obstructive-sleep-apnea-syndrome
#12
Xiao-Yi Wang, Shuang Wang, Xue Liu, Xiu Ding, Meng Li, De-Min Han
BACKGROUND: Obstructive sleep apnea syndrome (OSAS) has been shown to generate hypertension and endothelial dysfunction. Retinal vessel is the only vessel that can be observed directly and noninvasively; retinal vascular abnormalities can serve as a predictive marker for the occurrence, clinical course, and prognosis of cardiovascular and cerebrovascular diseases. The objective of this study was to identify the effect of OSAS severity on the morphological changes of retinal vessels. METHODS: Adult patients complained of snoring were included in this study...
April 5, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28338665/vessel-diameter-study-intravitreal-vs-posterior-subtenon-triamcinolone-acetonide-injection-for-diabetic-macular-edema
#13
M M Kurt, O Çekiç, Ç Akpolat, M Aslankurt, M Elçioğlu
PurposeTo detect and compare the vessel diameter effect of intravitreal vs subtenon injection of triamcinolone for diabetic macular edema (DME).MethodsSixty patients with DME who underwent triamcinolone injection either intravitreally (N=30) or under the tenon capsule (N=30) were included. Non-injected fellow eyes served as control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-vein ratio (AVR).ResultsIn the intravitreal group, pre-injection mean CRAE (147...
March 24, 2017: Eye
https://www.readbyqxmd.com/read/28337547/retinal-vascular-changes-after-vitrectomy-for-idiopathic-epiretinal-membrane-a-pilot-study-with-dynamic-vessel-analysis
#14
Lorenzo Iuliano, Giovanni Fogliato, Giuseppe Querques, Francesco Bandello, Marco Codenotti
PURPOSE: To investigate, using the Dynamic Vessel Analyzer (DVA), the retinal vascular changes that may occur after vitrectomy for idiopathic epiretinal membrane (ERM). METHODS: Twenty-six eyes of 13 patients affected by unilateral idiopathic ERM were prospectively analyzed. 13 fellow eyes were used as control. The static (central retinal artery and vein equivalents) and dynamic (after flicker light stimulus) DVA analysis was performed at baseline (1 day before surgery) and 6 months after vitrectomy...
March 23, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28335941/association-of-carotid-cavernous-fistula-with-central-retinal-vein-occlusion
#15
Miguel Cruz Pimentel, Stephanie Pappaterra, Juan F Batlle
No abstract text is available yet for this article.
April 2017: Ophthalmology
https://www.readbyqxmd.com/read/28335940/combined-central-retinal-vein-occlusion-and-central-retinal-arterial-obstruction-with-cilioretinal-artery-sparing
#16
Eric D Gaier, John B Miller, John I Loewenstein
No abstract text is available yet for this article.
April 2017: Ophthalmology
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#17
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28332380/angiographically-documented-macular-ischemia-after-single-bevacizumab-for-macular-edema-secondary-to-central-retinal-vein-occlusion
#18
Kyou Ho Lee, Eui Chun Kang, Hyoung Jun Koh
This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO). A 71-year-old female was treated with an intravitreal bevacizumab injection for macular edema following CRVO. Despite successfully decreased edema one month after injection, the postinjection best-corrected visual acuity immediately decreased from 20/40 to 20/1000 (Snellen equivalent). The FAZ area increased from 0...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#19
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315514/optic-nerve-head-in-central-retinal-vein-occlusion-by-spectral-domain-oct
#20
Antonio Longo, Teresio Avitabile, Maurizio G Uva, Vincenza Bonfiglio, Andrea Russo, Mario D Toro, Caterina Gagliano, Matteo Fallico, Michele Reibaldi
PURPOSE: To evaluate the morphology of optic nerve head by spectral-domain optical coherence tomography (SD-OCT) in patients with unilateral central retinal vein occlusion (CRVO). METHODS: In 39 consecutive patients with unilateral CRVO and 39 healthy controls, morphologic parameters of optic nerve head were assessed in both eyes by Spectralis SD-OCT using a custom radial B-scan pattern. The length of Bruch membrane opening (BMO) was measured in OCT scans, and optic disc diameters (DD) were assessed in infrared fundus photographs...
February 28, 2017: European Journal of Ophthalmology
keyword
keyword
53072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"